Share Price and Basic Stock Data
Last Updated: November 10, 2025, 2:49 pm
| PEG Ratio | 0.63 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Orchid Pharma Ltd operates in the pharmaceuticals sector and has reported a current share price of ₹704 with a market capitalization of ₹3,570 Cr. The company’s revenue from operations has shown a positive trajectory, with sales increasing from ₹560 Cr in FY 2022 to ₹666 Cr in FY 2023, and projected to reach ₹819 Cr in FY 2024. Quarterly sales figures demonstrate consistent growth, peaking at ₹221 Cr in December 2023 and ₹244 Cr in June 2024. This upward trend indicates a robust operational performance, particularly in a competitive industry where pharmaceutical companies often face regulatory and market challenges. The company’s operating profit margin (OPM) stood at 8% overall, with quarterly fluctuations reflecting operational efficiency, peaking at 19% in March 2023. Such performance illustrates Orchid Pharma’s ability to navigate market conditions effectively, although it remains essential to monitor future sales trends and external factors that could impact growth.
Profitability and Efficiency Metrics
Orchid Pharma’s profitability metrics present a mixed picture. The company’s net profit rose to ₹100 Cr in FY 2025 from a mere ₹46 Cr in FY 2023, indicating a significant improvement in its bottom line. The earnings per share (EPS) also reflected this growth, increasing to ₹19.65 in FY 2025 from ₹11.35 in FY 2023. However, the return on equity (ROE) stood at 8.21%, which is moderate compared to industry benchmarks, suggesting that while profitability is improving, it still has room for enhancement. Efficiency metrics like the cash conversion cycle (CCC) stood at 166 days, indicating a relatively longer duration for converting investments into cash, which could affect liquidity. The interest coverage ratio (ICR) was a healthy 9.95x, indicating that the company is generating sufficient earnings to cover its interest obligations, showcasing financial stability amidst its operational challenges.
Balance Sheet Strength and Financial Ratios
Orchid Pharma’s balance sheet shows a total debt of ₹175 Cr against reserves of ₹1,217 Cr, highlighting a solid equity base relative to its borrowings. The debt-to-equity ratio is low at 0.13, indicating prudent financial management and a lower risk of default. The current ratio stood at 2.83, well above the typical industry standard of 1.5, suggesting strong liquidity and the ability to meet short-term obligations. Additionally, the book value per share increased to ₹249.86 in FY 2025 from ₹168.72 in FY 2023, reflecting a strengthening asset position. However, the price-to-book value ratio at 3.11x suggests that the stock may be trading at a premium, which could deter value-focused investors. Overall, the balance sheet presents a strong financial position, but the premium valuation may raise concerns for potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Orchid Pharma indicates a strong promoter holding of 69.84%, which reflects significant insider confidence in the company’s future. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), held 1.39% and 19.43%, respectively, as of March 2025. The rise in DII participation from 2.98% in September 2022 to 20.10% in March 2025 signifies growing institutional interest and confidence in the company’s strategic direction. Conversely, the decline in promoter holding from 89.96% in September 2022 to 69.84% in March 2025 may raise concerns about insider selling or dilution of control. The total number of shareholders increased to 39,827, showcasing an expanding retail investor base, which is a positive indicator of market confidence. This evolving shareholding structure reflects a balance between institutional and retail interests, essential for maintaining stability in the stock price.
Outlook, Risks, and Final Insight
Orchid Pharma’s outlook appears cautiously optimistic, bolstered by strong revenue growth and improving profitability metrics. However, the company faces several risks, including potential regulatory challenges in the pharmaceutical sector and reliance on a limited product portfolio, which could impact future growth. The relatively high cash conversion cycle may also pose liquidity risks if not managed effectively. On the positive side, the strong institutional interest and solid financial ratios reflect confidence in the company’s operational and financial health. Moving forward, effective management of operational efficiency and sustained revenue growth will be crucial. Potential scenarios include continued growth if the company can diversify its product offerings and address operational inefficiencies, or a slowdown should market competition intensify or regulatory hurdles arise, impacting profitability and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Orchid Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 138 Cr. | 110 | 247/84.3 | 31.5 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,949 Cr. | 454 | 479/192 | 111 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 37.0 Cr. | 25.3 | 29.1/17.0 | 38.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,885.57 Cr | 1,184.51 | 56.03 | 198.81 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 131 | 165 | 160 | 210 | 183 | 199 | 221 | 217 | 244 | 223 | 217 | 237 | 173 |
| Expenses | 119 | 147 | 146 | 170 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 209 | 159 |
| Operating Profit | 12 | 18 | 14 | 40 | 22 | 23 | 35 | 29 | 32 | 30 | 26 | 28 | 14 |
| OPM % | 10% | 11% | 9% | 19% | 12% | 12% | 16% | 13% | 13% | 14% | 12% | 12% | 8% |
| Other Income | 3 | 6 | 9 | 34 | 2 | 8 | 8 | 13 | 8 | 8 | 8 | 4 | 11 |
| Interest | 8 | 9 | 8 | 7 | 6 | 4 | 4 | 3 | 4 | 3 | 4 | 4 | 3 |
| Depreciation | 22 | 18 | 8 | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 9 |
| Profit before tax | -14 | -3 | 7 | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 22 | 19 | 14 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -10% | -1% | 0% | 0% | -0% | 0% |
| Net Profit | -15 | -5 | 8 | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 | 15 |
| EPS in Rs | -3.68 | -1.32 | 1.86 | 14.49 | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | 2.94 |
Last Updated: August 20, 2025, 5:55 am
Below is a detailed analysis of the quarterly data for Orchid Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 173.00 Cr.. The value appears to be declining and may need further review. It has decreased from 237.00 Cr. (Mar 2025) to 173.00 Cr., marking a decrease of 64.00 Cr..
- For Expenses, as of Jun 2025, the value is 159.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 209.00 Cr. (Mar 2025) to 159.00 Cr., marking a decrease of 50.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 14.00 Cr..
- For OPM %, as of Jun 2025, the value is 8.00%. The value appears to be declining and may need further review. It has decreased from 12.00% (Mar 2025) to 8.00%, marking a decrease of 4.00%.
- For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 7.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.94. The value appears to be declining and may need further review. It has decreased from 4.39 (Mar 2025) to 2.94, marking a decrease of 1.45.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:43 am
| Metric | Sep 2013n n 18m | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,948 | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 922 | 850 |
| Expenses | 1,837 | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 804 | 752 |
| Operating Profit | 110 | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 118 | 99 |
| OPM % | 6% | 18% | 20% | 0% | 4% | -2% | -6% | 7% | 10% | 13% | 14% | 13% | 12% |
| Other Income | 92 | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 27 | 31 |
| Interest | 523 | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 15 | 14 |
| Depreciation | 252 | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 35 | 35 |
| Profit before tax | -573 | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 96 | 81 |
| Tax % | -2% | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -0% | |
| Net Profit | -560 | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 100 | 85 |
| EPS in Rs | -79.21 | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 | 16.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -77.42% | 28.69% | 119.55% | -289.86% | 10.69% | 98.29% | 2400.00% | 100.00% | 8.70% |
| Change in YoY Net Profit Growth (%) | 0.00% | 106.11% | 90.86% | -409.40% | 300.54% | 87.60% | 2301.71% | -2300.00% | -91.30% |
Orchid Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 23% |
| 3 Years: | 249% |
| TTM: | -24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | % |
| 3 Years: | 33% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 11:55 am
Balance Sheet
Last Updated: September 10, 2025, 2:11 pm
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 |
| Reserves | 310 | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,217 |
| Borrowings | 3,204 | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 175 |
| Other Liabilities | 1,067 | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 246 |
| Total Liabilities | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
| Fixed Assets | 2,584 | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 633 |
| CWIP | 360 | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 50 |
| Other Assets | 1,706 | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 |
| Total Assets | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
Below is a detailed analysis of the balance sheet data for Orchid Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 51.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,217.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,119.00 Cr. (Mar 2024) to 1,217.00 Cr., marking an increase of 98.00 Cr..
- For Borrowings, as of Mar 2025, the value is 175.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 135.00 Cr. (Mar 2024) to 175.00 Cr., marking an increase of 40.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 246.00 Cr.. The value appears to be improving (decreasing). It has decreased from 249.00 Cr. (Mar 2024) to 246.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,688.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,554.00 Cr. (Mar 2024) to 1,688.00 Cr., marking an increase of 134.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 633.00 Cr.. The value appears strong and on an upward trend. It has increased from 620.00 Cr. (Mar 2024) to 633.00 Cr., marking an increase of 13.00 Cr..
- For CWIP, as of Mar 2025, the value is 81.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2024) to 81.00 Cr., marking an increase of 50.00 Cr..
- For Investments, as of Mar 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2024) to 50.00 Cr., marking an increase of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 925.00 Cr.. The value appears strong and on an upward trend. It has increased from 857.00 Cr. (Mar 2024) to 925.00 Cr., marking an increase of 68.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,688.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,554.00 Cr. (Mar 2024) to 1,688.00 Cr., marking an increase of 134.00 Cr..
Notably, the Reserves (1,217.00 Cr.) exceed the Borrowings (175.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2013n n 18m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 317.00 | 168.00 | 0.00 | 21.00 | -15.00 | -597.00 | -424.00 | -213.00 | -247.00 | -24.00 | -57.00 | 110.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 96 |
| Inventory Days | 187 | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 219 |
| Days Payable | 220 | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 149 |
| Cash Conversion Cycle | -0 | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 166 |
| Working Capital Days | -399 | -49 | -168 | -500 | -876 | -1,158 | 166 | 302 | 97 | 54 | 118 | 135 |
| ROCE % | -3% | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 8% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 1,534,919 | 0.78 | 87.28 | 1,534,919 | 2025-04-22 17:25:24 | 0% |
| Quant Multi Asset Fund | 1,262,596 | 6.23 | 71.8 | 1,262,596 | 2025-04-22 17:25:24 | 0% |
| Nippon India Pharma Fund | 1,000,000 | 0.92 | 56.87 | 1,000,000 | 2025-04-22 17:25:24 | 0% |
| Quant Value Fund | 668,432 | 4.29 | 38.01 | 668,432 | 2025-04-22 17:25:24 | 0% |
| UTI Small Cap Fund | 445,000 | 0.73 | 25.3 | 445,000 | 2025-04-22 17:25:24 | 0% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 269,667 | 0.47 | 15.33 | 269,667 | 2025-04-22 17:25:24 | 0% |
| Tata Multi Asset Opportunities Fund | 175,260 | 0.48 | 9.97 | 175,260 | 2025-04-22 17:25:24 | 0% |
| Tata India Pharma & HealthCare Fund | 175,000 | 1.32 | 9.95 | 175,000 | 2025-04-22 17:25:24 | 0% |
| UTI Healthcare Fund | 100,000 | 0.67 | 5.69 | 100,000 | 2025-04-22 17:25:24 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
| Diluted EPS (Rs.) | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
| Cash EPS (Rs.) | 25.69 | 25.30 | 25.30 | 21.71 | -1.87 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 249.86 | 230.58 | 168.72 | 158.61 | 159.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 249.86 | 230.58 | 168.72 | 158.61 | 159.96 |
| Revenue From Operations / Share (Rs.) | 181.77 | 161.55 | 163.14 | 137.09 | 110.26 |
| PBDIT / Share (Rs.) | 28.52 | 27.91 | 25.25 | 15.22 | 15.93 |
| PBIT / Share (Rs.) | 21.71 | 21.35 | 11.82 | -6.10 | -10.76 |
| PBT / Share (Rs.) | 18.84 | 18.13 | 13.54 | -13.94 | -23.34 |
| Net Profit / Share (Rs.) | 18.88 | 18.74 | 11.88 | 0.38 | -28.55 |
| NP After MI And SOA / Share (Rs.) | 19.65 | 18.17 | 11.35 | -0.47 | -28.55 |
| PBDIT Margin (%) | 15.69 | 17.27 | 15.47 | 11.10 | 14.44 |
| PBIT Margin (%) | 11.94 | 13.21 | 7.24 | -4.44 | -9.75 |
| PBT Margin (%) | 10.36 | 11.22 | 8.29 | -10.16 | -21.16 |
| Net Profit Margin (%) | 10.38 | 11.60 | 7.27 | 0.28 | -25.89 |
| NP After MI And SOA Margin (%) | 10.80 | 11.24 | 6.95 | -0.34 | -25.89 |
| Return on Networth / Equity (%) | 7.86 | 7.88 | 6.72 | -0.30 | -17.84 |
| Return on Capital Employeed (%) | 7.85 | 8.37 | 5.65 | -2.86 | -4.00 |
| Return On Assets (%) | 5.90 | 5.93 | 3.78 | -0.17 | -9.41 |
| Long Term Debt / Equity (X) | 0.10 | 0.10 | 0.21 | 0.32 | 0.65 |
| Total Debt / Equity (X) | 0.13 | 0.11 | 0.48 | 0.41 | 0.65 |
| Asset Turnover Ratio (%) | 0.56 | 0.58 | 0.57 | 0.47 | 0.30 |
| Current Ratio (X) | 2.83 | 3.04 | 1.35 | 1.87 | 3.87 |
| Quick Ratio (X) | 1.68 | 2.03 | 0.73 | 1.15 | 2.79 |
| Inventory Turnover Ratio (X) | 3.12 | 2.14 | 2.02 | 2.09 | 1.60 |
| Interest Coverage Ratio (X) | 9.95 | 8.65 | 3.20 | 1.94 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 7.59 | 6.81 | 1.50 | -0.77 | -0.85 |
| Enterprise Value (Cr.) | 3934.97 | 5169.07 | 1869.70 | 1420.30 | 10472.28 |
| EV / Net Operating Revenue (X) | 4.27 | 6.31 | 2.81 | 2.54 | 23.27 |
| EV / EBITDA (X) | 27.20 | 36.52 | 18.14 | 22.86 | 161.10 |
| MarketCap / Net Operating Revenue (X) | 4.27 | 6.47 | 2.36 | 2.07 | 22.36 |
| Price / BV (X) | 3.11 | 4.53 | 2.28 | 1.79 | 15.41 |
| Price / Net Operating Revenue (X) | 4.27 | 6.47 | 2.36 | 2.07 | 22.36 |
| EarningsYield | 0.02 | 0.01 | 0.02 | 0.00 | -0.01 |
After reviewing the key financial ratios for Orchid Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.69. This value is within the healthy range. It has increased from 25.30 (Mar 24) to 25.69, marking an increase of 0.39.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 181.77. It has increased from 161.55 (Mar 24) to 181.77, marking an increase of 20.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.52. This value is within the healthy range. It has increased from 27.91 (Mar 24) to 28.52, marking an increase of 0.61.
- For PBIT / Share (Rs.), as of Mar 25, the value is 21.71. This value is within the healthy range. It has increased from 21.35 (Mar 24) to 21.71, marking an increase of 0.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.84. This value is within the healthy range. It has increased from 18.13 (Mar 24) to 18.84, marking an increase of 0.71.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.88. This value is within the healthy range. It has increased from 18.74 (Mar 24) to 18.88, marking an increase of 0.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 18.17 (Mar 24) to 19.65, marking an increase of 1.48.
- For PBDIT Margin (%), as of Mar 25, the value is 15.69. This value is within the healthy range. It has decreased from 17.27 (Mar 24) to 15.69, marking a decrease of 1.58.
- For PBIT Margin (%), as of Mar 25, the value is 11.94. This value is within the healthy range. It has decreased from 13.21 (Mar 24) to 11.94, marking a decrease of 1.27.
- For PBT Margin (%), as of Mar 25, the value is 10.36. This value is within the healthy range. It has decreased from 11.22 (Mar 24) to 10.36, marking a decrease of 0.86.
- For Net Profit Margin (%), as of Mar 25, the value is 10.38. This value exceeds the healthy maximum of 10. It has decreased from 11.60 (Mar 24) to 10.38, marking a decrease of 1.22.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 11.24 (Mar 24) to 10.80, marking a decrease of 0.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 15. It has decreased from 7.88 (Mar 24) to 7.86, marking a decrease of 0.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.85. This value is below the healthy minimum of 10. It has decreased from 8.37 (Mar 24) to 7.85, marking a decrease of 0.52.
- For Return On Assets (%), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 5.93 (Mar 24) to 5.90, marking a decrease of 0.03.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.13, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 2.83. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.83, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.68, marking a decrease of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.12. This value is below the healthy minimum of 4. It has increased from 2.14 (Mar 24) to 3.12, marking an increase of 0.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.95. This value is within the healthy range. It has increased from 8.65 (Mar 24) to 9.95, marking an increase of 1.30.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.59. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 7.59, marking an increase of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,934.97. It has decreased from 5,169.07 (Mar 24) to 3,934.97, marking a decrease of 1,234.10.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.31 (Mar 24) to 4.27, marking a decrease of 2.04.
- For EV / EBITDA (X), as of Mar 25, the value is 27.20. This value exceeds the healthy maximum of 15. It has decreased from 36.52 (Mar 24) to 27.20, marking a decrease of 9.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
- For Price / BV (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 3. It has decreased from 4.53 (Mar 24) to 3.11, marking a decrease of 1.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Orchid Pharma Ltd:
- Net Profit Margin: 10.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.85% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.86% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 49.6 (Industry average Stock P/E: 56.03)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.13
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.38%
FAQ
What is the intrinsic value of Orchid Pharma Ltd?
Orchid Pharma Ltd's intrinsic value (as of 10 November 2025) is 830.72 which is 0.39% lower the current market price of 834.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,232 Cr. market cap, FY2025-2026 high/low of 1,998/604, reserves of ₹1,217 Cr, and liabilities of 1,688 Cr.
What is the Market Cap of Orchid Pharma Ltd?
The Market Cap of Orchid Pharma Ltd is 4,232 Cr..
What is the current Stock Price of Orchid Pharma Ltd as on 10 November 2025?
The current stock price of Orchid Pharma Ltd as on 10 November 2025 is 834.
What is the High / Low of Orchid Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Orchid Pharma Ltd stocks is 1,998/604.
What is the Stock P/E of Orchid Pharma Ltd?
The Stock P/E of Orchid Pharma Ltd is 49.6.
What is the Book Value of Orchid Pharma Ltd?
The Book Value of Orchid Pharma Ltd is 250.
What is the Dividend Yield of Orchid Pharma Ltd?
The Dividend Yield of Orchid Pharma Ltd is 0.00 %.
What is the ROCE of Orchid Pharma Ltd?
The ROCE of Orchid Pharma Ltd is 8.07 %.
What is the ROE of Orchid Pharma Ltd?
The ROE of Orchid Pharma Ltd is 8.21 %.
What is the Face Value of Orchid Pharma Ltd?
The Face Value of Orchid Pharma Ltd is 10.0.